Teva Pharmaceutical Industries Ltd.’s launch in late January of a more convenient formulation of its soon-to-be-generic multiple sclerosis blockbuster Copaxone (glatiramer acetate injection) puts payors in a quandary and tests their ability to control utilization of the increasingly costly MS specialty category of drugs. (SeeAlso see "Copaxone Reduces Its Dosing Schedule, But Can It Shrink The Competition?" - Pink Sheet, 31 January, 2014..)
They must choose whether to position the new, three-times-weekly version of Copaxone favorably on formularies, similar to the flexible standing...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?